Xcelerate Inc. (OTCPK:XCRT) signed a non-binding letter of intent to acquire HS Pharmaceuticals, LLC on May 6, 2021. The LOI provides for XCRT to undertake its due diligence wherein its world-renowned team of clinicians and researchers will review HS Pharmaceuticals' operations, structure, and intellectual property. Xcelerate, Inc. today announced that it has signed a Definitive Memorandum of Understanding (DMOU) with HS Pharmaceuticals, LLC on August 26, 2021. The DMOU calls for the drafting and signing of an Acquisition Agreement with a pre-determined valuation of HS Pharmaceuticals. Under the terms of the DMOU will also acquire 51% stake in HS Cosmetics, Inc.